Trial Profile

Phase IB/II clinical study of HX009 in patients with lymphoma who have failed standard therapy

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 25 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HX 009 (Primary)
Indications Lymphoma
Focus Adverse reactions

Most Recent Events

25 May 2023 New trial record
22 May 2023 According to a HanX Biopharmaceuticals media release, the company has received Investigational New Drug (IND) approval from the FDA to initiate this study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com